Browse > Article
http://dx.doi.org/10.11620/IJOB.2021.46.4.176

Characterization of intracellular Ca2+ mobilization in gefitinib-resistant oral squamous carcinoma cells HSC-3 and -4  

Kim, Mi Seong (Department of Oral Physiology, Institute of Biomaterial-Implant, School of Dentistry, Wonkwang University)
Kim, Min Seuk (Department of Oral Physiology, Institute of Biomaterial-Implant, School of Dentistry, Wonkwang University)
Publication Information
International Journal of Oral Biology / v.46, no.4, 2021 , pp. 176-183 More about this Journal
Abstract
Oral squamous cell carcinoma (OSCC) metastasis is characterized by distant metastasis and local recurrence. Combined chemotherapy with cisplatin and 5-fluorouracil is routinely used to treat patients with OSCC, and the combined use of gefitinib with cytotoxic drugs has been reported to enhance the sensitivity of cancer cells in vitro. However, the development of drug resistance because of prolonged chemotherapy is inevitable, leading to a poor prognosis. Therefore, understanding alterations in signaling pathways and gene expression is crucial for overcoming the development of drug resistance. However, the altered characterization of Ca2+ signaling in drug-resistant OSCC cells remains unclear. In this study, we investigated alterations in intracellular Ca2+ ([Ca2+]i) mobilization upon the development of gefitinib resistance in human tongue squamous carcinoma cell line (HSC)-3 and HSC-4 using ratiometric analysis. This study demonstrated the presence of altered epidermal growth factor- and purinergic agonist-mediated [Ca2+]i mobilization in gefitinib-resistant OSCC cells. Moreover, Ca2+ content in the endoplasmic reticulum, store-operated calcium entry, and lysosomal Ca2+ release through the transient receptor potential mucolipin 1, were confirmed to be significantly reduced upon the development of apoptosis resistance. Consistent with [Ca2+]i mobilization, we identified modified expression levels of Ca2+ signaling-related genes in gefitinib-resistant cells. Taken together, we propose that the regulation of [Ca2+]i mobilization and related gene expression can be a new strategy to overcome drug resistance in patients with cancer.
Keywords
Squamous cell carcinoma of head and neck; Gefitinib; Drug resistance; Calcium channel;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Monteith GR, Davis FM, Roberts-Thomson SJ. Calcium channels and pumps in cancer: changes and consequences. J Biol Chem 2012;287:31666-73. doi: 10.1074/jbc.R112.343061.   DOI
2 Bryant JA, Finn RS, Slamon DJ, Cloughesy TF, Charles AC. EGF activates intracellular and intercellular calcium signaling by distinct pathways in tumor cells. Cancer Biol Ther 2004;3:1243-9. doi: 10.4161/cbt.3.12.1233.   DOI
3 Mantel A, Harvey V. P2X7/PANX1 as a new target for melanoma? Exp Dermatol 2015;24:336-7. doi: 10.1111/exd.12633.   DOI
4 Morgan AJ, Platt FM, Lloyd-Evans E, Galione A. Molecular mechanisms of endolysosomal Ca2+ signalling in health and disease. Biochem J 2011;439:349-74. doi: 10.1042/BJ20110949.   DOI
5 Jung J, Cho KJ, Naji AK, Clemons KN, Wong CO, Villanueva M, Gregory S, Karagas NE, Tan L, Liang H, Rousseau MA, Tomasevich KM, Sikora AG, Levental I, van der Hoeven D, Zhou Y, Hancock JF, Venkatachalam K. HRAS-driven cancer cells are vulnerable to TRPML1 inhibition. EMBO Rep 2019;20:e46685. doi: 10.15252/embr.201846685.   DOI
6 Berridge MJ, Lipp P, Bootman MD. The versatility and universality of calcium signalling. Nat Rev Mol Cell Biol 2000;1:11-21. doi: 10.1038/35036035.   DOI
7 Frederick BA, Helfrich BA, Coldren CD, Zheng D, Chan D, Bunn PA Jr, Raben D. Epithelial to mesenchymal transition predicts gefitinib resistance in cell lines of head and neck squamous cell carcinoma and non-small cell lung carcinoma. Mol Cancer Ther 2007;6:1683-91. doi: 10.1158/1535-7163. MCT-07-0138.   DOI
8 Di Virgilio F, Sarti AC, Falzoni S, De Marchi E, Adinolfi E. Extracellular ATP and P2 purinergic signalling in the tumour microenvironment. Nat Rev Cancer 2018;18:601-18. doi: 10.1038/s41568-018-0037-0.   DOI
9 VanHouten J, Sullivan C, Bazinet C, Ryoo T, Camp R, Rimm DL, Chung G, Wysolmerski J. PMCA2 regulates apoptosis during mammary gland involution and predicts outcome in breast cancer. Proc Natl Acad Sci U S A 2010;107:11405-10. doi: 10.1073/pnas.0911186107.   DOI
10 Machado E, White-Gilbertson S, van de Vlekkert D, Janke L, Moshiach S, Campos Y, Finkelstein D, Gomero E, Mosca R, Qiu X, Morton CL, Annunziata I, d'Azzo A. Regulated lysosomal exocytosis mediates cancer progression. Sci Adv 2015; 1:e1500603. doi: 10.1126/sciadv.1500603.   DOI
11 Grandis JR, Tweardy DJ. Elevated levels of transforming growth factor alpha and epidermal growth factor receptor messenger RNA are early markers of carcinogenesis in head and neck cancer. Cancer Res 1993;53:3579-84.
12 Di Gennaro E, Barbarino M, Bruzzese F, De Lorenzo S, Caraglia M, Abbruzzese A, Avallone A, Comella P, Caponigro F, Pepe S, Budillon A. Critical role of both p27KIP1 and p21CIP1/WAF1 in the antiproliferative effect of ZD1839 ('Iressa'), an epidermal growth factor receptor tyrosine kinase inhibitor, in head and neck squamous carcinoma cells. J Cell Physiol 2003;195:139-50. doi: 10.1002/jcp.10239.   DOI
13 Zhang P, Zhang Z, Zhou X, Qiu W, Chen F, Chen W. Identification of genes associated with cisplatin resistance in human oral squamous cell carcinoma cell line. BMC Cancer 2006;6:224. doi: 10.1186/1471-2407-6-224.   DOI
14 Cui C, Merritt R, Fu L, Pan Z. Targeting calcium signaling in cancer therapy. Acta Pharm Sin B 2017;7:3-17. doi: 10.1016/j.apsb.2016.11.001.   DOI
15 Kondratska K, Kondratskyi A, Yassine M, Lemonnier L, Lepage G, Morabito A, Skryma R, Prevarskaya N. Orai1 and STIM1 mediate SOCE and contribute to apoptotic resistance of pancreatic adenocarcinoma. Biochim Biophys Acta 2014;1843:2263-9. doi: 10.1016/j.bbamcr.2014.02.012.   DOI
16 Li RF, Man QW, Liu JY, Zheng YY, Gao X, Liu HM. Overexpression of T-type calcium channel Cav3.1 in oral squamous cell carcinoma: association with proliferation and antiapoptotic activity. J Mol Histol 2021;52:511-20. doi: 10.1007/s10735-020-09937-x.   DOI
17 Di Virgilio F, Adinolfi E. Extracellular purines, purinergic receptors and tumor growth. Oncogene 2017;36:293-303. doi: 10.1038/onc.2016.206.   DOI
18 Bugshan A, Farooq I. Oral squamous cell carcinoma: metastasis, potentially associated malignant disorders, etiology and recent advancements in diagnosis. F1000Res 2020;9:229. doi: 10.12688/f1000research.22941.1.   DOI
19 Magne N, Fischel JL, Dubreuil A, Formento P, Marcie S, Lagrange JL, Milano G. Sequence-dependent effects of ZD1839 ('Iressa') in combination with cytotoxic treatment in human head and neck cancer. Br J Cancer 2002;86:819-27. doi: 10.1038/sj.bjc.6600103.   DOI
20 Rubin Grandis J, Melhem MF, Gooding WE, Day R, Holst VA, Wagener MM, Drenning SD, Tweardy DJ. Levels of TGF-alpha and EGFR protein in head and neck squamous cell carcinoma and patient survival. J Natl Cancer Inst 1998;90:824-32. doi: 10.1093/jnci/90.11.824.   DOI
21 Berridge MJ, Bootman MD, Roderick HL. Calcium signalling: dynamics, homeostasis and remodelling. Nat Rev Mol Cell Biol 2003;4:517-29. doi: 10.1038/nrm1155.   DOI
22 Flourakis M, Lehen'kyi V, Beck B, Raphael M, Vandenberghe M, Abeele FV, Roudbaraki M, Lepage G, Mauroy B, Romanin C, Shuba Y, Skryma R, Prevarskaya N. Orai1 contributes to the establishment of an apoptosis-resistant phenotype in prostate cancer cells. Cell Death Dis 2010;1:e75. doi: 10.1038/cddis.2010.52.   DOI
23 Cohen EE, Rosen F, Stadler WM, Recant W, Stenson K, Huo D, Vokes EE. Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol 2003;21:1980-7. doi: 10.1200/JCO.2003.10.051.   DOI
24 Khalil A, Jameson MJ. The EGFR inhibitor gefitinib enhanced the response of human oral squamous cell carcinoma to cisplatin in vitro. Drugs R D 2017;17:545-55. doi: 10.1007/s40268-017-0204-x.   DOI